Stephen Locarnini

机构：The Royal Melbourne Hospital, The University of Melbourne, Victorian Infectious Diseases Reference Laboratory, Peter Doherty Institute, Melbourne Health

发表论文 98 篇 · 总被引 5758 次 · h-index 29

代表论文

Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡ (2019 · Journal of Hepatology · 被引 364)
Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB (2022 · Journal of Hepatology · 被引 106)
Estimating the global prevalence of hepatitis B (2015 · The Lancet · 被引 72)
Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen supression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment (2020 · Journal of Hepatology · 被引 40)
GS-12-Ascending dose cohort study of inarigivir - A novel RIG I agonist in chronic HBV patients: Final results of the ACHIEVE trial (2019 · Journal of Hepatology · 被引 31)
PS-080-Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU/ml threshold (2019 · Journal of Hepatology · 被引 31)